China News Service, November 10, according to Reuters, on the 9th local time, the US pharmaceutical company Eli Lilly’s experimental new crown antibody therapy obtained emergency use authorization from the US Food and Drug Administration (FDA). The therapy is mainly aimed at Out-of-hospital COVID-19 patients who are over 65 or have certain chronic diseases.

On November 9, local time, citizens lined up for testing at a new crown pneumonia testing station in Queens, New York City, USA.

The latest statistics of the new crown epidemic released by Johns Hopkins University in the United States on the 9th showed that the cumulative number of confirmed cases in the United States has exceeded 10 million.

Photo by China News Agency reporter Liao Pan

　　The FDA stated that its emergency use authorization is based on clinical trials showing that Eli Lilly’s monoclonal antibody therapy bamlanivimab reduces the possibility of hospitalization or emergency treatment for high-risk patients.

The FDA said it can be used to treat mild to moderate COVID-19 patients, mainly for adults and children over 12 years old.

This antibody therapy is not suitable for patients who are hospitalized due to infection with the new crown or who need oxygen therapy.

　　In early October, Eli Lilly applied to the FDA for emergency use authorization for its monoclonal antibody therapy.

At the end of October, a study published in a peer-reviewed journal found that 1.6% of the 452 mild-to-moderate COVID-19 patients who received antibody injections required hospitalization or emergency room visits. Among patients who received placebo injections, this The ratio is 6.3%.

　　Eli Lilly has stated that it plans to seek similar authorization for its double antibody cocktail therapy in November.

The company claims that double antibody cocktail therapy is more helpful in reducing virus levels than single antibody therapy.

　　According to reports, Eli Lilly expects to supply up to 1 million doses of monoclonal antibody therapy drugs in the fourth quarter of 2020, and 100,000 doses in October.

It has reached a deal with the U.S. government for US$1,250 per dose and plans to sell it to other countries.

　　Several other drugmakers, including Regeneron Pharmaceuticals, are also testing new crown antibody therapies.

U.S. President Trump received an antibody treatment from Regeneron Pharmaceuticals after contracting the new coronavirus in early October.

American infectious disease expert Fauci said that this may help his recovery.